Elucidation of intestinal absorption mechanism of carvedilol-loaded solid lipid nanoparticles using Caco-2 cell line as an in-vitro model

References

• Mehnert W, Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 2001;47:165–196
   PubMed Web of Science ®Google Scholar
• Cavalli R, Gasco MR, Chetoni P, et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002;238:241–245
   PubMed Web of Science ®Google Scholar
• Rawat M, Singh D, Saraf S, et al. Lipid carriers: a versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi 2008;128:269–280
   PubMed Web of Science ®Google Scholar
• Rawat MK, Jain A, Singh S. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation. J Pharm Sci 2011;100:2366–2378
   PubMed Web of Science ®Google Scholar
• Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008;34:1394–1405
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–177
   PubMed Web of Science ®Google Scholar
• Severino PC, Souto EB, Pinho SC, et al. Hydrophilic coating of mitotane-loaded lipid nanoparticles: preliminary studies for mucosal adhesion. Pharm Dev Technol 2011;18:577–581
   PubMedGoogle Scholar
• Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release 2005;107:215–228
   PubMed Web of Science ®Google Scholar
• Tsai MJ, Huang YB, Wu PC, et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral valuations. J Pharm Sci 2011;100:547–557
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Tabbakhian M, Mohammadi MY. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res 2010;20:286–296
   PubMed Web of Science ®Google Scholar
• Yang S, Zhu J, Lu Y, et al. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999;16:751–757
   PubMed Web of Science ®Google Scholar
• Muller RH, Runge S, Ravelli V, et al. Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 2006;317:82–89
   PubMed Web of Science ®Google Scholar
• Hu L, Jia H, Luo Z, et al. Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles. Pharmazie 2010;65:110–113
   PubMed Web of Science ®Google Scholar
• Luo Y, Chen D, Ren L, et al. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release 2006;114:53–59
   PubMed Web of Science ®Google Scholar
• Yang L, Geng Y, Li H, et al. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie 2009;64:86–89
   PubMed Web of Science ®Google Scholar
• Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007;6:231–248
   PubMed Web of Science ®Google Scholar
• Pouton CW, Porter CJ. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev 2008;60:625–637
   PubMed Web of Science ®Google Scholar
• Nanjwade BK, Patel DJ, Udhani RA, et al. Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs. Sci Pharm 2011;79:705–727
   PubMedGoogle Scholar
• Beg S, Swain S, Rizwan M, et al. Bioavailability enhancement strategies: basics, formulation approaches and regulatory considerations. Curr Drug Deliv 2011;8:691–702
   PubMed Web of Science ®Google Scholar
• Porter CJ, Charman WN. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev 2001;50:S127–S147
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Shukla D, Mishra B, et al. Lipid – an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 2009;73:1–15
   PubMed Web of Science ®Google Scholar
• Bargoni A, Cavalli R, Caputo O, et al. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 1998;15:745–750
   PubMed Web of Science ®Google Scholar
• Dodiya SS, Chavhan SS, Sawant KK, et al. Solid lipid nanoparticles and nanosuspension formulation of Saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies. J Microencapsul 2011;28:515–527
   PubMed Web of Science ®Google Scholar
• Dong Z, Xie S, Zhu L, et al. Preparation and in vitro, in vivo evaluations of norfloxacin-loaded solid lipid nanopartices for oral delivery. Drug Deliv 2011;18:441–450
   PubMed Web of Science ®Google Scholar
• Luo CF, Yuan M, Chen MS, et al. Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. Int J Pharm 2011;410:138–144
   PubMed Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J Drug Target 2006;14:632–645
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Charman WN, Porter CJH. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 2008;60:702–716
   PubMed Web of Science ®Google Scholar
• Taipalensuu J, Tornblom H, Lindberg G, et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 2001;299:164–170
   PubMed Web of Science ®Google Scholar
• Corti G, Maestrelli F, Cirri M, et al. Development and evaluation of an in vitro method for prediction of human drug absorption: I. Assessment of artificial membrane composition. Eur J Pharm Sci 2006;27:346–353
   PubMed Web of Science ®Google Scholar
• Corti G, Maestrelli F, Cirri M, et al. Development and evaluation of an in vitro method for prediction of human drug absorption: II. Demonstration of the method suitability. Eur J Pharm Sci 2006;27:354–362
   PubMed Web of Science ®Google Scholar
• Gaumet M, Gurny R, Delie F. Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur J Pharm Sci 2009;36:465–473
   PubMed Web of Science ®Google Scholar
• Desai M, Labhasetwar V, Amidon G, et al. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996;13:1838–1845
   PubMed Web of Science ®Google Scholar
• Caliph SM, Charman WN, Porter CJH. Effect of short-, medium-, and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats. J Pharm Sci 2000;89:1073–1084
   PubMed Web of Science ®Google Scholar
• Shah MK, Madan P, Lin S. Preparation, in vitro evaluation and statistical optimization of carvedilol-loaded solid lipid nanoparticles for lymphatic absorption via oral administration. Pharm Dev Technol 2014;19:475–485
   PubMed Web of Science ®Google Scholar
• Schnurr E, Widmann L, Glocke M. Efficacy and safety of carvedilol in the treatment of hypertension. J Cardiovasc Pharmacol 1987;10:S101–S107
   Google Scholar
• Dupont AG. Effects of carvedilol on renal function. Eur J Clin Pharmacol 1990;38:S96–S100
   PubMed Web of Science ®Google Scholar
• Tamilvanan S, Bangale GS. Ananthi JJ, et al. Carvedilol-loaded mucoadhesive buccal tablets: influence of various mucoadhesive polymers on drug release behavior. PDA J Pharm Sci Technol 2009;63:196–206
   PubMedGoogle Scholar
• Lanlan W, Peinan S, Shufang N, et al. Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev Ind Pharm 2005;31:785–794
   PubMedGoogle Scholar
• Xu LX, Hui N, Ma LY, et al. Study on fluorescence property of carvedilol and determination of carvedilol by fluorimetry. Spectrochim Acta A Mol Biomol Spectrosc 2005;61:855–859
   PubMed Web of Science ®Google Scholar
• Sanjula B, Shah FM, Javed A, et al. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target 2009;17:249–256
   PubMed Web of Science ®Google Scholar
• Kukec S, Dreu R, Vrbanec T, et al. Characterization of agglomerated carvedilol by hot-melt processes in a fluid bed and high shear granulator. Int J Pharm 2012;430:74–85
   PubMedGoogle Scholar
• Misra A, Kalariya M, Padhi B, et al. Methotraxate loaded solid lipid nanoparticles for topical treatment of psoriasis: formulation & clinical implications. Drug Del Tech 2004;4:1–12
   Google Scholar
• Furuichi K, Ra C, Isersky C, et al. Comparative evaluation of the effect of pharmacological agents on endocytosis and coendocytosis of IgE by rat basophilic leukaemia cells. Immunology 1986;58:105–110
   PubMedGoogle Scholar
• Schmid SL, Carter LL. ATP is required for receptor-mediated endocytosis in intact cells. J Cell Biol 1990;111:2307–2318
   PubMed Web of Science ®Google Scholar
• Martins AS, Ordonez JL, Amaral AT, et al. IGF1R signaling in Ewing sarcoma is shaped by clathrin-/caveolin-dependent endocytosis. PLoS One 2011;6:e19846
   Web of Science ®Google Scholar